Beacon Therapeutics
Clinical-stage gene therapy company developing treatments for retinal diseases such as X-linked retinitis pigmentosa.
beacontx.com ↗Why it's here
Closed an oversubscribed Series C of over $75M led by Goldman Sachs Alternatives in January 2026.
source: beacontx.com- Focus
- Ophthalmic Gene Therapy
- Founded
- 2022
- Latest round
- Series C, $75M+, Jan 2026
- London office
- Rolling Stock Yard, 2nd floor, 188 York Way, Islington N7 9ASsource: beacontx.com
- London presence
- HQsource: app.dealroom.co
- Investors
- Goldman Sachs Alternatives (lead), Advent Life Sciences, Forbion, Oxford Science Enterprises, Retinal Degeneration Fund, Synconasource: beacontx.com
- Area
- King's Cross
- Nearest station
- Caledonian Road & Barnsbury, 580 m
Verified 6 Oct 2026. How we verify · Suggest a fix
For Beacon Therapeutics
Work here? Show you're on the map. Add the badge to your site or README, or share the listing.
<a href="https://londonmempool.co.uk/c/beacon-therapeutics"><img src="https://londonmempool.co.uk/badge/beacon-therapeutics.svg" alt="Beacon Therapeutics is listed on London Mempool" width="361" height="28"></a>
Add ?theme=light to the image URL for light backgrounds.
Same building
2 more companies on the map list this office address.